Irene Gañán‐Gómez

Author

Irene Gañán‐Gómez

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

I Ganan-Gomez, I Gañán-Gómez, I Gomez, I. Ganan-Gomez, I. Gañán-Gómez, Irene G. Herrera Gomez, Irene Ganan Gomez, Irene Ganan- Gomez, Irene Ganan-Gomez, Irene Ganan Gomez

134

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Universidad de Alcalá Michigan Medicine University of California, Los Angeles Dana-Farber Cancer Institute

About

Irene Gañán‐Gómez is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	729
2	Cell Biology	7	7	441
3	Immunology	7	7	520
4	Health Sciences	1	1	19
5	Biochemistry	1	1	12

Irene Gañán‐Gómez

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Toll-like receptor alterations in myelodysplastic syndrome Yue Wei, Sophie Dimicoli, Carlos E. Bueso‐Ramos, Leukemia Toll-like ReceptorsToll-like Receptor AlterationsAutoimmune DiseaseHematologyImmunology	2013	158
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma Matteo Marchesini, Yamini Ogoti, Elena Fiorini, Cancer Cell Hematological MalignancyTranscriptional RegulationImmunologyRna SplicingPathology	2017	158
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy Guillermo Montalban‐Bravo, Rashmi Kanagal‐Shamanna, Koji Sasaki, Blood Advances	2019	111
Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome Simona Colla, Derrick Sek Tong Ong, Yamini Ogoti, Cancer Cell Myelodysplastic SyndromeBone Marrow FailureGeneticsHematologyMedicine	2015	103
Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells Yue Wei, R Chen, Sophie Dimicoli, Leukemia Hematological MalignancyImmunogeneticsInnate Immunity SignalingImmunologyGene Expression	2013	86
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study Alexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, The Lancet Haematology Hematological MalignancyMedicineHematologyPathologyHigh-risk Myelodysplastic Syndromes	2022	79
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy Irene Gañán‐Gómez, Hui Yang, Feiyang Ma, Nature Medicine	2022	76
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms Guillermo Montalban‐Bravo, Koichi Takahashi, Keyur P. Patel, Oncotarget	2018	63
PAX4 Defines an Expandable β-Cell Subpopulation in the Adult Pancreatic Islet Petra I. Lorenzo, Esther Fuente-Martín, Thierry Brun, Scientific Reports	2015	58
Overexpression of miR-125a in Myelodysplastic Syndrome CD34+ Cells Modulates NF-κB Activation and Enhances Erythroid Differentiation Arrest Irene Gañán‐Gómez, Yue Wei, Hui Yang, PLoS ONE ImmunologyImmune RegulationPathologyInnate ImmunityImmune System	2014	45

Page 1